Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 26, 2016 - Issue 1
Submit an article Journal homepage
1,074
Views
10
CrossRef citations to date
0
Altmetric
Reviews

Emerging small-molecule compounds for treatment of atopic dermatitis: a review

Kateřina VávrováSkin Barrier Research Group, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech RepublicView further author information
Pages 21-34 | Published online: 15 Oct 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.
  • Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.

** Current treatment guidelines – part 1 focused on methods for diagnosis and monitoring AD

  • Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.

** Current treatment guidelines – part 2 focused on nonpharmacological interventions and topical treatments (corticosteroids and calcineurin inhibitors, antimicrobials and antihistamines)

  • Eichenfield LF, Basu S, Calvarese B, et al. Effect of desonide hydrogel 0.05% on the hypothalamic‐pituitary‐adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol. 2007;24(3):289–295.
  • Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991;25(6):1149–1152.
  • Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.

** Current treatment guidelines – part 3 focused on phototherapy and systemic treatments (immunomodulators, antimicrobials and antihistamines)

  • Darsow U, Pfab F, Valet M, et al. Pruritus and atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):237–244.
  • Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218–1233.

** Current treatment guidelines – part 4 focused on treatments for flare prevention, educational interventions, coexisting allergies, dietary interventions and environmental modifications

* Useful review of AD drugs in clinical trials, both small-molecular and peptide compounds, and the current status of clinical evidence

* Useful review of AD medications in clinical trials

* Useful review of the new treatment modalities in AD

* Useful review of the increasing evidence that the inflammation in AD results primarily from inherited abnormalities in epidermal permeability barrier plus a summary of lipid-based approaches to corrective therapy

  • Elias PM. Stratum corneum defensive functions: an integrated view. J Gen Intern Med. 2005;20(5):183–200.

* Useful review on the multiple defensive functions of the stratum corneum, their structural and biochemical basis, clinical consequences and therapeutic implications

  • Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genetics. 2006;38(4):441–446.
  • Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214–219.
  • Scott IR, Harding CR. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev Biol. 1986;115(1):84–92.
  • Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules: source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta. 1982;719(1):110–117.
  • Rabionet M, Gorgas K, Sandhoff R. Ceramide synthesis in the epidermis. Biochim Biophys Acta. 2014;1841(3):422–434.

* Useful review on epidermal ceramide biosynthesis and its regulation

  • Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta. 2014;1841(3):280–294.

* Useful review on the skin barrier lipids

  • Holleran WM, Takagi Y, Uchida Y. Epidermal sphingolipids: metabolism, function, and roles in skin disorders. Febs Letters. 2006;580(23):5456–5466.

* Useful review on the role of ceramides and glycosylceramide and sphingomyelin processing in skin diseases including AD

  • Kovacik A, Roh J, Vavrova K. The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family. ChemBioChem. 2014;15(11):1555–1562.

* Useful review on unique epidermal 6-hydroxyceramides in healthy and diseased skin

  • Kabashima K, Otsuka A, Egawa G, et al. Filaggrin production promoter, therapeutic agent for diseases associated with reduction in production of filaggrin, and method for screening for said therapeutic agent. WO 2014017319. 2014.
  • Burns FJ, Labuda I. Compositions and methods for restoring the stratum corneum and treating dermatological diseases. US 20140249234. 2014.
  • Lee SH, Lee SH. Composition for promoting the generation of filaggrin. KR 20110006890. 2011.
  • Kiso A, Murakami T. Filaggrin production promoter. JP 2010090037. 2010.
  • Voegel J, At E, Rosignoli C. Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis. US 20100291002. 2010.
  • Lee HK, Cho BW. Pharmaceutical composition containing glutamine for treating atopic dermatitis. WO 2010021514. 2010.
  • Gibbs NK. Medicament. EP 2254575. 2010.
  • Woo BY, Jang WH, Joo YH, et al. Novel pseudoceramide compound and production method for same. WO 2014084676. 2014.
  • Kim DH, An EJ, Hwang JS, et al. Pseudolipid complex mixture and a skin external application composition containing same. EP 2769709. 2014.
  • Uchida Y, Holleran WM, Elias PM. On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides. J Dermatol Sci. 2008;51(1):37–43.
  • Szulc ZM, Bielawska A, Obeld LM, et al. Sphingo-guanidines and their use as inhibitors of sphingosine kinase. US 20120035268. 2012.
  • Martinez A, Gil C. Camp-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Exp Opin Ther Patents. 2014;24(12):1311–1321.
  • Holden CA, Chan SC, Hanifin JM. Monocyte localization of elevated camp phosphodiesterase activity in atopic dermatitis. J Invest Dermatol. 1986;87(3):372–376.
  • Rudra S, Gupta N, Chandrakant KG, et al. Phosphodiestarase inhibitors. US 20120004201. 2012.
  • Rudra S, Gupta N, Baregama LK, et al. Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors. US 8420666. 2013.
  • Rudra S, Gupta N, Baregama LK, et al. Inhibitors of phosphodiesterase type-iv. US 20110021473. 2011.
  • Palle VP, Balachandran S, Gupta N, et al. Condensed isoxaline derivatives as inhibitors of phosphodiesterase type – iv. US 20090048247. 2009.
  • Gharat LA, Gopalan B, Joshi NK. Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as pde 4 inhibitors. US 7943634. 2011.
  • Gopalan B, Manojit P, Shrikant HH, et al. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation. WO 2009115874. 2009.
  • Lewis RA, Soter NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol. 1982;129(4):1627–1631.
  • Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193(2):255–262.
  • Cosmi L, Annunziato F, Iwasaki M, et al. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol. 2000;30(10):2972–2979.
  • Crosignani S, Jorand-Lebrun C, Cleva C, et al. Phenoxy acetic acid derivatives. WO 2010092043. 2010.
  • Crosignani S, Jorand-Lebrun C, Grippi-Vallotton T. Tricyclic indole-derived spiro derivatives as crth2 modulators. WO 2011006936. 2011.
  • Schwarz M, Sebille E, Cleva C, et al. Tricyclic spiro derivatives as crth2 modulators. WO 2006125784. 2006.
  • Armer RE, Wynne GM, Dorgan CR, et al. Compounds having crth2 antagonist activity. EP 2492268. 2012.
  • Hunter MG, Pettipher ER, Perkins CM, et al. Use of crth2 antagonist compounds. US 20110124683. 2011.
  • Collins LP, Perkins CM, Hunter M, et al. Crth2 antagonists for treatment of eosinophilic diseases and conditions. US 20130052190. 2013.
  • Armer RE, Pettipher ER, Whittaker M, et al. Compounds having crth2 antagonist activity. US 20140039012. 2014.
  • Aslanian RG, Biju PJ, Boyce CW, et al. Quinazolinone-type compounds as crth2 antagonists. WO 2012051036. 2012.
  • Anderskewitz R, Martyres D, Oost T, et al. Pyrazole compounds as crth2 antagonists. WO 2012101043. 2012.
  • Buil AMA, Roberts RS, Sevilla GS. New pyrazole derivatives having crth2 antagonistic behaviour. WO 2012069175. 2012.
  • Bouyssou T, Gupta A, Seither P. Pharmaceutical compositions for treatment of respiratory and inflammatory diseases. WO 2012013566. 2012.
  • Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine. 1991;3(3):165–183.
  • Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Ann Rev Immunol. 1994;12(1):593–633.
  • Li Y, Bacon K, Sugimoto H, et al. 2-phenoxy- and 2-phenylsulfonamide derivatives with ccr3 antagonistic activity for the treatment of inflammatory or immunological disorders. US 20140005176. 2014.
  • Li Y, Watanabe A, Lowinger TB, et al. Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders. US 20100204213. 2010.
  • Ly TW, Forrester JA. Arylsulfonamide ccr3 antagonists. NZ 620092. 2015.
  • Baaum ED, Ly TW, Tran MCSY. 2,5-disubstituted arylsulfonamide ccr3 antagonists. NZ 620048. 2015.
  • Lim JW, Kim JH, Oak MH, et al. Piperazinyl 3-aminopyrrolidine derivatives as a ccr2 antagonists. US 8575173. 2013.
  • Miller MW, Scott JD. Bipiperidinyl derivatives useful as inhibitors of chemokine receptors. US 7652142. 2010.
  • Hughes RO, Devraj RV, Rogier DJ, et al. 3-aminocyclopentanecarboxamides as chemokine receptor agonists. US 8293903. (2012).
  • Yang L, Lin S, Morriello G, et al. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity. US 20100234409. 2010.
  • Fine JS, Kim SH, Anilkumar GN, et al. Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines. WO 2009020534. 2009.
  • Ong PY. Emerging drugs for atopic dermatitis. Exp Opin Emerging Drugs. 2009;14(1):165–179.
  • Badertscher K, Brönnimann M, Karlen S, et al. Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res. 2005;296(10):503–506.
  • Tanaka T, Imajo S, Tomimori Y, et al. Oral administration of chymase inhibitor improves dermatitis in NC/Nga mice. J Invest Dermatol. 2007;127:971–973.
  • Takeuchi J, Inukai T, Sakai M. Novel imidazopyridine compound. US 20120094944. 2012.
  • Muto T, Tanaka T, Futamura J, et al. Seven-membered ring compound and pharmaceutical use therefor. US 8846660. 2014.
  • Bennett NJ, Mcinally T, Mochel T, et al. Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis. WO 2009067081. 2009.
  • Mailland F, Caserini M. Use of pidotimod to treat atopic dermatitis. WO 2014094839. 2014.
  • Braxmeier T, Friedrichson T, Jennings G. Methods for the treatment and amelioration of atopic dermatitis. US 20110263531. 2011.
  • Maurer M, Magerl M, Metz M, et al. Miltefosine: a novel treatment option for mast cell-mediated diseases. J Dermatol Treat. 2011;24(4):244–249.
  • Sohn J, Kim T-I, Yoon Y-H, et al. Transglutaminase inhibitor: a new anti-inflammatory approach in allergic conjunctivitis. J Clin Invest. 2003;111:121–128.
  • Kim SY, Lee C, Lee AY. Composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them. US 20120156137. 2012.
  • Chambon P, Metzger D, Li M. Methods for generating mammalian models of atopic diseases, and screening for their treatment. US 20100144683. 2010.
  • Brosz M, Kuhne FW, Blaszkiewitz K, et al. Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis. US 20130295200. 2013.
  • McGrath MS, Benike C, Kuehne FW, et al. Effect of WF10 (TCDO) on antigen presentation. Transplant Proc. 1998;30(8):4200–4204.
  • McGrath MS, Kodelja V. Balanced macrophage activation hypothesis: a biological model for development of drugs targeted at macrophage functional states. Pathobiology. 1999;67(5–6):277–281.
  • Whitlock GA, Glossop PA. 2-(-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinase (syk) inhibitors. US 2015232470. 2015.
  • Bolli M, Lescop C, Mathys B, et al. 2-methoxy-pyridin-4-yl-derivatives. NZ 614367. 2015.
  • Tasler S, Baumgartner R, Saeb W, et al. IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation. NZ 613592. 2015.
  • Tasler S, Saeb W, Leban J, et al. IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation. NZ 613656. (2015).
  • Nazir T, Baxter AD, Rothaul A Methods and compositions for the treatment of pruritus. US 20090093509. 2009.
  • Stander S, Luger TA. Itch in atopic dermatitis – pathophysiology and treatment. Acta Dermatovenerol Croat. 2010;18(4):289–296.

* Useful review of the mechanisms of induction of itch in AD and possibilities for target-specific therapies

* Useful review of drugs in preclinical and clinical development for the management of pruritus

* Useful review on the pharmacological development for chronic pruritus in inflammatory dermatoses, chronic kidney diseases and hepatobiliary diseases

  • Valle FD, De Petrocellis L, Maione S, et al. Pharmacological preparation for topical use containing n-palmitoyl-vanillamide. US 20140066399. 2014.
  • De Petrocellis L, Guida F, Moriello AS, et al. N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. Pharmacol Res. 2011;63(4):294–299.
  • Neufang G, Schläger T, Voigt N, et al. Cosmetic or dermatological preparation for prophylaxis and/or treatment of atopic dermatitis. WO 2014060150. 2014.
  • Davidson S, Giesler GJ. The multiple pathways for itch and their interactions with pain. Trends Neurosci. 2010;33(12):550–558.
  • Doğrul A, Seyrek M, Yeşilyrut Ö. The use of 5-ht7 receptor antagonists including some atypical antipsychotics as antipruritic agents. WO 2013154513. 2013.
  • Mommert S, Gschwandtner M, Gutzmer R, et al. The role of the histamine H4 receptor in atopic dermatitis. Curr Allergy Asthma Rep. 2011;11(1):21–28.

* Useful review summarizing the current data regarding the activity of the histamine H4 receptor on the key effector cells in AD and possible use as a treatment target

  • Kiss R, Keseru GM. Novel histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat. 2014;24(11):1185–1197.
  • Ho PS, Yoon DO, Han SY, et al. Novel heterocyclic derivatives and their uses. US 20140315888. 2013.
  • Cheung MD, Lalwani D Methods for treatment of atopic dermatitis and inflammatory skin disorders. US 20140235618. 2014.
  • Grimalt R, Mengeaud V, Cambazard F, et al. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61–67.
  • Chamlin SL, Frieden IJ, Fowler A, et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol. 2001;137(8):1110–1112.
  • Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47(2):198–208.
  • Vavrova K, Hrabalek A, Mac‐Mary S, et al. Ceramide analogue 14S24 selectively recovers perturbed human skin barrier. Brit J Dermatol. 2007;157(4):704–712.
  • Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10(5):531–537.
  • Mao-Qiang M, Brown BE, Wu-Pong S, et al. Exogenous nonphysiologic vs physiologic lipids: divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131(7):809–816.
  • Zhang Q. Topically applied ceramide accumulates in skin glyphs. Clin Cosmet Invest Dermatol. 2015;8:329–337.
  • Novotný J, Pospěchová K, Hrabálek A, et al. Synthesis of fluorescent c 24-ceramide: evidence for acyl chain length dependent differences in penetration of exogenous NBD-ceramides into human skin. Bioorg Med Chem Lett. 2009;19(24):6975–6977.
  • Skolova B, Hudska K, Pullmannova P, et al. Different phase behavior and packing of ceramides with long (c16) and very long (c24) acyls in model membranes: infrared spectroscopy using deuterated lipids. J Phys Chem B. 2014;118(35):10460–10470.
  • Wolf R, Parish LC. Barrier-repair prescription moisturizers: do we really need them? Facts and controversies. Clin Dermatol. 2013;31(6):787–791.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.